Statement re Issuance of Patent

PROTEOME SCIENCES plc

PRESS RELEASE

Issuance of TMT® Patent in Canada

13th December 2006. Proteome Sciences plc is pleased to announce that it has
today received the official Letters Patent for Canadian Patent Number 2,460,131
entitled "Mass Markers" which was granted on November 21st 2006. The claims of
the issued patent relate to specific isobaric mass tag structures which
represent one class of Proteome Sciences Tandem Mass Tag® (TMT®) technology.
The patent term is 20 years from 16th September 2002.

There are currently two international patent applications relating to TMT.
Canadian Patent Number 2,460,131 was the second TMT® patent (TMT2) to be filed
and claims isobaric mass tags with peptide structures and various methods of
their use. The earlier TMT® patent (TMT1) is in process of prosecution at the
Canadian Intellectual Property Office.

Commenting on the issuance Christopher Pearce, Chief Executive of Proteome
Sciences said:

"Recent events, including the launch of isobaric mass tags by Perkin Elmer
(ExacTags) and new applications for the isobaric iTRAQ mass tags by Applied
Biosystems highlight the growing recognition of the importance of these
reagents across life sciences research. We have been working on the development
of a number of TMT functions to enhance our own biomarker discovery, validation
and measurement efforts and to improve the ProteoSHOP® offering to our
customers with particular emphasis on supporting applications in pre-clinical
pharmaceutical discovery and clinical trials of new drugs.

The issuance of one of the TMT® family of patents in Canada is another
significant milestone in the company's development. It validates the
patentability of the TMT® isobaric mass tags in a sizeable economic market and
underpins the value of our pending TMT1 and TMT2 applications in other
territories.

This has increased the profile and economic value of our isobaric mass tags and
will be incorporated into the TMT® licence negotiations.

We anticipate that issuance of the first Canadian patent relating to the TMT®
technology will shortly be followed by further progress with both TMT1 and TMT2
applications in other territories."

Ends

Notes to editors:

Proteome Sciences plc

Proteome Sciences, a global leader in applied proteomics, uses high sensitivity
proprietary technologies to detect differentially expressed proteins in
diseases. The protein biomarkers discovered in body fluids or tissues are
validated, developed and commercialised as diagnostic, prognostic or
therapeutic products through strategic alliances and out-licensing.

Through its unique ProteoSHOP® toolbox, Proteome Sciences provides high
sensitivity/high throughput proteomics solutions, including traditional two
dimensional gel-based electrophoresis (2DE) and proprietary gel-free protein
sequence tag technologies (PST®, qPST™& TMT®), to major pharma, biotechnology
and diagnostic companies, to discover and exploit protein biomarkers.
Sensitizer® chemical mass tags have been developed separately as a series of
stand-alone reagents.

For further information please visit www.proteomics.com .

Enquiries:

Proteome Sciences plc

Dr. Ian Pike, Business Development Director

Email: [e-mail]

Christopher Pearce, Chief Executive Officer

Email: [e-mail]

Tel: [phone]

Public Relations for Proteome Sciences

IKON Associates

Adrian Shaw

Tel: [phone]

Mobile: [phone]

Email: [e-mail]